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Article 10

Serious Infections Can Guard Against Tumor Growth
by Steven Bradt

S

erious infections can retard and even
halt the growth of tumors in mammals
by blocking the formation of blood vessels that nourish those tumors, researchers at
the School have found. The finding, reported
in the Cutting Edge section of the May 15 issue
of the Journal of Immunology, offers researchers
an important new lead on ways to block angiogenesis, the growth of new small arteries and
veins.
“This finding suggests that infected animals
could be a source of new, extremely potent
inhibitors of angiogenesis, the Holy Grail of
modern anti-cancer research,” said lead author
Andrei Thomas-Tikhonenko, an assistant professor of pathology at the School.
The result also turns on its head decades of
dogma among immunologists, who had
believed that when the cells of the immune system were mobilized against life-threatening
infections, tumors also fell victim to this fortification of the body’s defenses. Now, ThomasTikhonenko’s work has shown that during
infection tumors don’t grow even in animals
with severely weakened immune systems. This
indicates that it’s the suppression of angiogenesis, not antigen-battling lymphocytes and
macrophages, that holds the key to this longrecognized phenomenon.
“This is a whole new way of looking at how
cancer can be inhibited in mammals,” said John
Hibbs, professor of internal medicine and chief
of the Infectious Disease Division at the University of Utah, who has conducted research on
infection-mediated suppression of tumorigenesis. “For a number of years, immunologists
have regarded this process as a cytotoxic effect
mediated by lymphocytes and activated
macrophages. This work shows that infections
also inhibit tumors by a surprisingly different
mechanism.”
Thomas-Tikhonenko’s research, which has
not fingered a specific factor that blocks angiogenesis in infected animals, creates a kind of
scientific whodunit. The Penn team is searching for the mystery molecules, pressed into
service by infections, that so strongly inhibit
the growth of vascular tissues inside the
tumors.
“We are very much interested in identification of these ‘culprits’ because we believe that
they will be extremely useful therapeutic agents
not only for cancer but also for other diseases

where unwanted angiogenesis takes place,”
Thomas-Tikhonenko said. Angiogenesis is
known to play a role in diabetic retinopathy, a
leading cause of blindness, and endometriosis,
a major contributor to female infertility.
The first observation that infection interferes with tumor growth was made more than
100 years ago by a New York surgeon, William
B. Coley, who noted that streptococcal infection caused regression of soft tissue sarcomas
in human patients. Traditionally, this resistance
has been explained by stimulation of antitumor immunity.
“However, direct proof of this mechanism
has never been obtained, and therapies based
on it have not materialized,” ThomasTikhonenko said. “In our paper, we demonstrate, for the first time, that infection-induced
resistance need not involve any of the immune
responses that might limit tumor growth.”
Two separate lines of evidence suggested to
the Penn researchers that the immune system
doesn’t play a crucial role in inhibiting tumors.
First, in strains of mice lacking the cells normally found on the front lines of the immune
system — T-lymphocytes, macrophages and
NK cells — tumor growth was nevertheless
suppressed when the protozoan Toxoplasma
gondii was contracted. Further support came
from the earlier observation that the tumor
under investigation, the B16 variant of malignant melanoma, produced no antigens recognizable to the mouse’s immune system.
After he had ruled out the immune system
as intermediary between infection and tumorigenesis, Thomas-Tikhonenko was tipped off to
angiogenesis’ role by co-author and toxoplasmosis expert Christopher Hunter, associate
professor of parasitology at the School. Hunter
suggested that the same mouse proteins
designed to guard the host against Toxoplasma
gondii might also inhibit growth of blood vessels. This suggestion proved correct: in a pilot
experiment, the injection of powerful angiogenic compounds into mice with toxoplasmosis failed to induce growth of new blood vessels
under the skin, a phenomenon that has important implications for cancer.
The tiniest of tumors don’t require their
own blood vessels, relying on simple diffusion
of oxygen and nutrients from nearby cells. But
by the time they’ve grown to two or three millimeters in size, tumors need the nourishment
provided by blood vessels in order to survive.

The laboratories of Thomas-Tikhonenko and
William Lee at Penn’s School of Medicine
found that at this stage, where angiogenesis
becomes crucial, melanomas developing in
infected mice experience severe lack of oxygen
but are unable to recruit new endothelial cells
to produce blood vessels.
Thomas-Tikhonenko’s findings suggest that
Toxoplasma gondii-infected animals could be
used to purify molecules that halt the sustenance of tumors. Although several antiangiogenic compounds have been recently
identified, their efficacies are yet to be proven
in clinical trials and none of them has been
approved by the Food and Drug Administration for the treatment of cancer patients.
The drive to pinpoint the exact chemical
factor that prompts infections to block angiogenesis will likely take months, possibly years.
“It might be a combination of well-known
molecules such as interferons or an entirely
new compound,” Hunter said.
Thomas-Tikhonenko and Hunter’s coauthors on the Journal of Immunology paper
are Duonan Yu, Cam Ngo, Cinzia Sevignani,
Michael Goldschmidt and Sidney Evans of
Penn’s School of Veterinary Medicine; Michael
Gee and William Lee of Penn’s School of Medicine; and Tatyana Golovkina of the Jackson
Laboratory in Bar Harbor, Me. Their work was
funded by the National Institute of Allergy and
Infectious Diseases, the National Cancer Institute and the University of Pennsylvania Cancer
Center Pilot Projects Program.

New Faculty Member
Dr. Ilana Reisner has been appointed
assistant professor of behavioral medicine
and director of VHUP’s behavior clinic. Dr.
Reisner came to Penn from Cornell University’s College of Veterinary Medicine where
she was a visiting fellow. She received her
D.V.M. degree from the Veterinary College
at Oregon State University and then went to
Cornell for a Ph.D. in behavioral physiology
with an interest in canine aggression.
During part of her residency in behavioral
medicine at Cornell, Dr. Reisner was a
Morris Animal Foundation Fellow. Dr.
Reisner became a diplomate of the American College of Veterinary Behaviorists in
1995.
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